Decisions / 5056
final resolution2021-10-12active

Arzneimittel-Richtlinie/Anlage XII: Niraparib (Neues Anwendungsgebiet: Ovarialkarzinom, Eileiterkarzinom oder primäres Peritonealkarzinom, FIGO-Stadien III und IV, Erhaltungstherapie) – Therapiekosten

Open official decision page ↗

G-BA source · retrieved 2026-08-05

Decision orientation

What the G-BA did

3 cited claims

Each claim links to the official G-BA page or an exact PDF page range.

Official metadata

Decision date
2021-10-12
Effective
13.10.2021
Action type
final resolution
Committee
Arzneimittel

Case context

Listed normative targets

directiveArzneimittel-Richtlinie
directive annexAnlage XII: Nutzenbewertung nach § 35a SGB V

A listed target is not treated as a new directive version unless an official version source exists.

Official document package